Attovia Therapeutics Prices Upsized IPO at $17 Per Share, Raising $289 Million

Attovia Therapeutics, Inc. (Nasdaq: ATTO), a clinical-stage biopharmaceutical company, announced it has priced its upsized initial public offering at $17.00 per share. The company expects to raise approximately $289.0 million in gross proceeds before underwriting discounts and other expenses, according to a company press release.

Offering Details

Attovia is offering 17,000,000 shares of its common stock, with all shares being sold by the company. The offering was increased in size from its initial plans, a move that can suggest healthy investor demand.

Underwriters have been granted a 30-day option to purchase up to an additional 2,550,000 shares at the IPO price. The stock is scheduled to begin trading on the Nasdaq Global Market on August 5, 2026, under the ticker symbol "ATTO", with the offering expected to close on August 6, 2026, subject to customary closing conditions.

Pipeline and Use of Proceeds

Attovia Therapeutics focuses on developing biotherapeutics for immune-mediated diseases. The capital raised from the IPO is expected to fund the advancement of its clinical programs and general corporate purposes.

Ad

The company's development pipeline includes:

• ATTO-1310: A lead candidate in clinical development as an anti-IL-31 therapeutic for chronic pruritic (itch-related) diseases.
• ATTO-2306: A candidate in IND-enabling studies for atopic dermatitis.
• ATTO-1091: A candidate in IND-enabling studies for inflammatory bowel disease.

Market Context

A syndicate of investment banks is managing the offering, with Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets serving as joint book-running managers. LifeSci Capital is acting as a passive book-running manager.

The U.S. Securities and Exchange Commission (SEC) declared the company's registration statement effective on August 4, 2026, a key regulatory clearance required before the IPO could be priced and shares sold to the public.